Purple biotech presents data of its phase 1 head & neck cancer of nt219 in combination with cetuximab at esmo tat congress 2024

Nt219 was well tolerated anti-tumor activity at relevant higher dose levels observed with 29% objective response rate (orr) and 71% disease control rate (dcr) rehovot, israel, feb. 27, 2024 (globe newswire) --    purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced clinical results from its phase 1/2 dose escalation study of nt219 in combination with cetuximab in the treatment of patients with recurrent/metastatic head and neck cancer (r/m scchn).
PPBT Ratings Summary
PPBT Quant Ranking